Literature DB >> 15252162

Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients.

Masato Nishimura1, Tetsuya Hashimoto, Hiroyuki Kobayashi, Toyofumi Fukuda, Koji Okino, Noriyuki Yamamoto, Naoto Nakamura, Toshikazu Yoshikawa, Hakuo Takahashi, Toshihiko Ono.   

Abstract

BACKGROUND: Patients with diabetic nephropathy are likely to have neurological complications including cardiovascular autonomic dysfunction, which is related to increased risk of mortality. We investigated whether cardiovascular autonomic neuropathy is associated with left ventricular hypertrophy (LVH) in diabetic haemodialysis patients.
METHODS: Holter electrocardiography was carried out for 24 h with time and frequency domain analyses of heart rate variability in 154 diabetic (age 62+/-11 years) and 63 non-diabetic haemodialysis patients (62+/-10 years). The left ventricular mass index (LVMI) was determined by echocardiography. We used the percentage of differences exceeding 50 ms between adjacent normal RR intervals (pNN50) in time domain analysis and the power in the high-frequency range (HF: 0.15-0.40 Hz) in frequency domain analysis as indicators of parasympathetic activity.
RESULTS: The mean LVMI was greater in diabetic than in non-diabetic patients (168+/-63 vs 144+/-54 g/m(2), P<0.01). LVMI inversely correlated with pNN50 (r = -0.270, P = 0.0007, n = 154) and HF (r = -0.277, P = 0.0005, n = 154) in diabetic patients, but not in non-diabetic patients. By multiple logistic analysis, LVH was strongly associated with pNN50 (odds ratio 0.088; 0, <2%; 1, >/=2%) and HF (odds ratio 0.058; 0, <500 ms(2); 1, >/=500 ms(2)) in diabetic patients.
CONCLUSIONS: Impaired parasympathetic activity, which indicates cardiovascular autonomic neuropathy, was associated with the presence of LVH in diabetic haemodialysis patients. The co-existence of cardiovascular autonomic neuropathy and LVH may be one of the key factors for the high incidence of cardiovascular events in diabetic haemodialysis patients.

Entities:  

Mesh:

Year:  2004        PMID: 15252162     DOI: 10.1093/ndt/gfh361

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

Review 1.  What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes.

Authors:  Rodica Pop-Busui
Journal:  J Cardiovasc Transl Res       Date:  2012-05-30       Impact factor: 4.132

Review 2.  Cardiovascular autonomic neuropathy: diagnosis and management.

Authors:  Aaron I Vinik; Tomris Erbas
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

3.  Effects of daily hemodialysis on heart rate variability: results from the Frequent Hemodialysis Network (FHN) Daily Trial.

Authors:  Christopher T Chan; Glenn M Chertow; John T Daugirdas; Tom H Greene; Peter Kotanko; Brett Larive; Andreas Pierratos; John B Stokes
Journal:  Nephrol Dial Transplant       Date:  2013-09-26       Impact factor: 5.992

4.  Risk factors for pulmonary hypertension in maintenance hemodialysis patients: a cross-sectional study.

Authors:  Yanjun He; Yuling Wang; Xingying Luo; Jianting Ke; Yi Du; Mi Li
Journal:  Int Urol Nephrol       Date:  2015-11       Impact factor: 2.370

5.  Determinants of cardiac autonomic dysfunction in ESRD.

Authors:  Christopher T Chan; Nathan W Levin; Glenn M Chertow; Brett Larive; Gerald Schulman; Peter Kotanko
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 8.237

Review 6.  Prognostic significance and therapeutic option of heart rate variability in chronic kidney disease.

Authors:  Jing Zhang; Ningning Wang
Journal:  Int Urol Nephrol       Date:  2013-03-29       Impact factor: 2.370

Review 7.  The management of diabetic neuropathy in CKD.

Authors:  Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman
Journal:  Am J Kidney Dis       Date:  2009-12-30       Impact factor: 8.860

8.  Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease.

Authors:  Huimin Chen; Ying Cui; Changying Xing; Yogendranath Purrunsing; Xiaoming Zha; Chong Shen; Ming Zeng; Guang Yang; Xiangbao Yu; Lina Zhang; Yao Jiang; Zhixiang Shen; Haoyang Ma; Caixia Yin; Yunfei Li; Ningning Wang
Journal:  Int Urol Nephrol       Date:  2018-10-25       Impact factor: 2.370

9.  Deterioration of Deceleration Capacity of Heart Rate is Associated with Left Ventricular Hypertrophy in End-Stage Renal Disease Population.

Authors:  Ting-Tse Lin; Wei-Shun Yang; Mu-Yang Hsieh; Chih-Chen Wu; Lian-Yu Lin
Journal:  Acta Cardiol Sin       Date:  2018-05       Impact factor: 2.672

10.  Regression of left ventricular hypertrophy in diabetic nephropathy: loss of parasympathetic function predicts response to treatment.

Authors:  Larry A Weinrauch; Andrew J Berger; Doron Aronson; Ray E Gleason; Annette T Lee; John A D'Elia
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.